13,784 Shares of Danaher Corporation $DHR Purchased by B. Riley Wealth Advisors Inc.

Key Points

• B. Riley Wealth Advisors purchased 13,784 Danaher shares worth approximately $3.05 million, while institutional investors collectively own 79.05% of the company.
• Danaher reported quarterly earnings of $1.94 per share, beating estimates of $1.85, as revenue increased 5.5% year over year to $6.26 billion.
• The company’s growth outlook is supported by its AI collaboration with NVIDIA and planned autonomous laboratory, while analysts maintain a “Moderate Buy” consensus with an average price target of $235.41.

B. Riley Wealth Advisors Inc. acquired a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 13,784 shares of the conglomerate's stock, valued at approximately $3,054,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in DHR. Main Street Group LTD bought a new position in shares of Danaher during the 1st quarter valued at about $25,000. N.E.W. Advisory Services LLC bought a new stake in shares of Danaher during the second quarter worth $25,000. Marquette Asset Management LLC raised its holdings in shares of Danaher by 192.1% during the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate's stock worth $25,000 after acquiring an additional 73 shares during the period. Evolution Wealth Management Inc. raised its holdings in shares of Danaher by 208.0% during the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate's stock worth $29,000 after acquiring an additional 104 shares during the period. Finally, Field & Main Bank acquired a new stake in shares of Danaher during the second quarter worth $29,000. Institutional investors own 79.05% of the company's stock.

Danaher Stock Performance

Shares of DHR stock opened at $224.65 on Thursday. The company has a fifty day moving average price of $212.92 and a two-hundred day moving average price of $195.39. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The stock has a market cap of $157.93 billion, a P/E ratio of 39.90, a P/E/G ratio of 2.80 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the previous year, the company posted $0.77 EPS. The firm's revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, equities analysts predict that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher's payout ratio is 28.42%.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Wall Street Analyst Weigh In

DHR has been the subject of a number of research analyst reports. Weiss Ratings raised shares of Danaher from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, September 16th. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Saturday, October 10th. Guggenheim upped their price objective on Danaher from $200.00 to $250.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. TD Cowen increased their price objective on Danaher from $236.00 to $255.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, The Goldman Sachs Group lifted their target price on Danaher from $210.00 to $250.00 and gave the company a "buy" rating in a research report on Monday, September 21st. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Danaher has a consensus rating of "Moderate Buy" and an average target price of $235.41.

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.